We evaluated the safety, efficacy and anti-tumor effects of a surgery adjuvant treatment on canine patients with malignant melanoma. This approach combined suicide gene therapy with a subcutaneous vaccine composed by formolized tumor cells and irradiated xenogeneic cells producing human interleukin-2 and granulocyte-macrophage colony-stimulating factor. The post-surgical margin of the cavity was infiltrated with lipid-complexed thymidine kinase suicide gene coadministrated with ganciclovir. Toxicity was minimal or absent in all patients. With respect to surgery-treated controls (SC), this combined treatment (CT) significantly increased the fraction of patients local disease-free from 6 to 58% and distant metastases-free from 43 to 78% (Fisher's Exact test).
Introduction
A key factor in ensuring the success of gene therapy is to develop a clear understanding of how it can best play a role in the clinic. Trials on spontaneous canine cancers can serve as a valuable bridge between pre-clinical studies and human clinical trials, decreasing the use of experimental laboratory animals. The dog offers an excellent research model due to its large size, spontaneous development of tumors, rapid assessment of therapeutic activity, similar response to environmental influences and biological similarity to humans. Tumor burdens in dogs with oral cancers are more similar to humans than the experimentally induced tumor volumes found in many murine models, and canine patients are generally less heavily pretreated than human patients entering clinical trials. 1, 2 Naturally occurring tumors in dogs have similar histopathologic features and biologic behavior, but develop twice as frequently and progress at a more rapid rate than in humans. In general, clinical trials using veterinary patients can be completed in one-fifth of the time (1-3 years) at significantly lower expense than similar human clinical trials. With a potentially large population of cases for investigation, time course is both long enough to allow comparison of response times, but short enough to ensure rapid collection of data. 1, 2 Canine malignant melanoma (CMM), a spontaneous and highly aggressive tumor of the oral cavity, digit/ footpad and mucocutaneous junctions, appears clinically similar to aggressive human melanoma. Both the diseases are chemo-and radio-resistant, do not respond well to treatment with conventional biological response modifiers such as Mycobacterium bovis BCG or Corynebacterium parvum extracts and share similar metastatic phenotypes and site selectivity. [1] [2] [3] Importantly, CMM is a syngeneic cancer occurring in outbred, immune competent large mammals that live in the same environment as humans do. For these reasons, we believe that CMM is a more clinically faithful therapeutic model for human melanoma when compared with the more traditional mouse/rat systems, and further use of CMM as a therapeutic model for human melanoma should be strongly encouraged. [1] [2] [3] Like in human melanoma, the prognosis for CMM correlates directly with tumor stage. 3, 4 At the time of diagnosis, the disease is often metastatic and has an extremely poor prognosis because of rapid invasion of surrounding normal tissue and high likelihood of regional and distant metastasis early in the course of the disease. [1] [2] [3] [4] The high metastatic rate observed with this disease and the inefficacy of current therapies, warranted further investigation into novel therapies.
Different gene therapy approaches have been reported for canine spontaneous melanoma such as: (i) xenogeneic ex vivo generated interleukin-2 (IL-2) producing engineered cells, 5 (ii) ex vivo generated granulocyte-macrophage colony-stimulating factor (GM-CSF) producing autologous tumor cells, 6 (iii) in vivo enterotoxin-B plus GM-CSF gene transfer, 7 (iv) in vivo xenogeneic human tyrosinase gene transfer, 8 (v) in vivo human FasL gene transfer 9 and ex vivo generated human gp100 producing allogeneic tumor cells. 10 Immunotherapy in combination with suicide gene therapy (SG) holds the most promise for malignant melanoma patients with minimal residual disease after surgery. [11] [12] [13] In a previous controlled study in more than 100 dogs, we demonstrated that repeated concurrent injections of the suicide gene system and engineered xenogeneic IL-2-and GM-CSF-secreting cells into the tumor bed, substantially controlled tumor growth and improved disease-free and overall survival in the treated animals compared to untreated or surgerytreated controls.
14 As a continuation of these encouraging data, we started a treatment adjuvant of surgery against the minimal residual disease whose rationale appeared to be considerably superior to our previous intra-tumor treatment.
14 This new treatment consisted of complete or cytoreductive surgery. The surgical margin of the cavity after tumor removal was treated with non-viral suicide gene therapy. Then, patients were treated with a subcutaneous vaccine (SV) composed of autologous and allogeneic formolized tumor cells and irradiated xenogeneic cells producing human IL-2 and human GM-CSF. Patients with local disease (unresectable or partially removed tumor, or post-surgical relapse) received into the remaining tumor multiple injections of suicide gene concurrent with SV.
Here, we demonstrate that the most optimal clinical setting was this surgery adjuvant treatment against minimal residual disease that not only prevented recurrence and the outgrowth of metastases, but significantly improved disease-free and overall survival compared to surgery-treated controls.
Results

Patients demographics
As seen in Table 1a , both the patients average and median ages were about 11 years, without any significant difference between genders or treatment groups. The combined treatment (CT) group was subjected to surgery plus suicide gene combined with a subcutaneous vaccine composed of cytokines secreting xenogeneic cells ( Figure  1 ). The control group of surgery-treated patients (SC) was composed of patients whose owners decided to proceed only with a surgical intervention under our clinical surveillance.
Various breeds were represented among SC and CT patients: mixed breed (35 and 39%), Pekingese (16 and 11%), German Shepherd (16 and 7%), Cocker Spaniel (6 and 14%), Doberman Pinscher (8 and 4%), Rottweiler (4 and 7%) and others (14 and 18%) (Table 1b) .
All surgery and combined treatment dogs (80 and 68% oral, 16 and 20% digital, 2 and 9% ocular, 2 and 2% anal and 0 and 1% mammary melanoma) were completely staged. The majority of dogs was classified as stage I-II, with negative (47%) or stage III (46%) with positive proximal lymph nodes. Only 7% of patients had lung metastases (stage IV) at the beginning of the trial ( Table 2 ).
The combined treatment controlled the local disease
Because of the advanced stage of the disease, when entered into the protocol, about 29% of the patients were Adjuvant combined therapy for canine malignant melanoma LME Finocchiaro and GC Glikin subjected to partial tumor resection (cytoreduction). In patients experiencing complete tumor resection, CT diminished local relapse to one-third of the value found for surgery controls (SC) and lymph node regional metastases to one-eighth (from SC 32 to CT 4%; data not shown). Forty-nine percent of the CT-treated patients remained without any post-surgical relapse compared to only 6% of the SC (Table 2) . For the sake of simplicity, local relapse was considered as recurrence in the same place, invasion of surrounding tissue and/or regional metastasis.
In those patients subjected to partial surgery (30%) or presenting local relapse (21%), weekly application of CT with additional serial suicide gene therapy induced a substantial local anti-tumor response on residual disease (Tables 2 and 3 ). This was evidenced by the patients presenting objective responses (49%) as a significant reduction (about 85%) in tumor size after five rounds of suicide gene treatment (Figure 2a ). At this point tumors were treated with suicide gene less frequently; every 14, 28 or 56 days, until they resolved or were judged having become unresponsive because of tumor progression.
The objective responses (complete 18%, partial 31%) were higher in patients with smaller tumors (Table 3, Figure 2b ). In addition, CT produced about 29% of the stable disease, while 22% of the dogs developed tumor progression. As shown in Table 3 , the median duration of patients local response significantly increased from nearly 6 to 9 months in non-responder to objective responder tumors respectively. However, the combined treatment increased almost three-and sevenfold, the median duration of non-responder and non-recurrent groups compared to those of surgery controls.
Taken together, CT patients who did not display postsurgical local relapse (49%) plus those who attained a complete response (9%), resulted in 58% of patients free of local disease (48% of them died or are still alive without any evidence of disease at the end of the study). Only 11% of the CT patients continued with progressive disease compared with 94% of SC. Adjuvant combined therapy for canine malignant melanoma LME Finocchiaro and GC Glikin In addition, in those patients who locally relapsed, the CT increased 2.6-fold the recurrence-free lapse compared to SC patients as derived from Kaplan-Meyer analysis (see Table 5 ).
The combined treatment controlled the systemic disease
The combined treatment succeeded in controlling the systemic disease as evidenced by the significantly higher percentage of metastasis-free patients at the end of the study (78%) compared to surgery controls (43%), as derived from Fisher's Exact test (Table 4) . It is noteworthy that CT augmented 4.9-fold the fraction of metastasis-free patients with respect to those that developed distant metastasis during the treatment. (Po0.00002, Fisher's Exact test). These two fractions were not significantly different in the SC group. For those patients that developed recurrence and/or distant metastases, the CT significantly delayed (2.9-fold) the first event appearance with respect to SC patients as derived from Kaplan-Meyer analysis (Table 5) . Fifty-one patients out of 100 (those subjected to cytoreduction or those presenting local recurrence) were clinically evaluated and treated as described in Figures 1 and 2 . Objective responses and stable disease were considered until they turned into progressive disease or death (whichever came first) while progressive disease duration was considered since it turned into progressive disease until the death of the patient. Values were derived from Kaplan-Meyer analysis (plots not shown).
P-values were calculated by Log-rank test for Kaplan-Meyer analysis. Adjuvant combined therapy for canine malignant melanoma LME Finocchiaro and GC Glikin
The combined treatment significantly prolonged patients survival
As evidenced by Kaplan-Meier analysis, the CT resulted in a 4.9-fold increase in median survival with respect to SC patients ( Figure 3 , Table 6 ). If we consider the event as death caused by melanoma, then we can censor the patients deceased from unrelated causes as alive on the day of death (no event). This assumption shifts the survival curve over 50% beyond 1312 days, precluding the calculation of median survival. The evidence shows a dramatic increase of CT patients survival expectation 416.8-fold compared to SC (Table 6 ).
The disease-, recurrence-and metastasis-free lapses of CT patients were significantly higher (about 10.7-, 18.0-and 411.7-fold) than the respective values for SC patients.
It is noteworthy that more than 50% of the CT patients never developed metastasis ( Figure 4 , Table 6 ).
Median overall survival of patients with complete tumor resection and/or free of local disease was substantially greater than that of dogs with partial tumor resection and/or local disease. In addition, dogs experiencing tumor control (g, objective responses plus stable disease), especially those presenting objective responses (e) survived significantly longer than non-responders and progressive disease groups (f and h) ( Table 7 ). The differences were more remarkable when survival because of melanoma rather than of any cause was considered. No effect on survival was observed with regard to tumor location, sex, or age (data not shown).
After more than a 3-year follow-up period, 42% of the CT-treated patients are alive, 26% of them still free of disease and 3% rising above 3 years survival, long exceeding dead patients' survival. Because of their advanced age and the remarkable increase in median overall survival, 47% of deceased patients subjected to CT died of unrelated causes, most of them free of melanoma (four patients died of a secondary malignancy), while 53% died or were humanely euthanized because of primary melanoma or metastases progression as seen in Table 8 . Conversely, the pattern that resulted was significantly different for deceased patients belonging to SC group; 98% dying because of melanoma (58% local tumor and 40% metastases progression).
Adjuvant treatments resulted innocuous
Toxicity was minimal or absent in all dogs. Repeated injections into the tumor bed of suicide gene plasmid DNA:DMRIE/DOPE lipoplexes, as well as subcutaneous administration of cytokine-secreting xenogeneic cells, showed safe, not allergenic results and could be applied repetitively. Fewer side effects were registered in some patients. They typically involved necrosis (47%) and a vitiligo-like tumor de-pigmentation at the sites of injection (in 20% of cases) as well as edema (30%), Figure 3 Kaplan-Meier analysis of overall survival. Overall survival (SC, CT), overall survival because of melanoma (SCM, CTM) were censored as described in Table 6 . SC: surgery controls. CT: combined treatment.
Adjuvant combined therapy for canine malignant melanoma LME Finocchiaro and GC Glikin swelling and itching (17%) at the injection sites and indurations (16%) after subcutaneous vaccine application. Neither significant changes in clinical and hematological parameters, nor local or systemic toxicity, nor organic dysfunction or fever during or at the completion of the study could be attributed to treatment. The proposed combined treatment significantly restored the patients' quality of life to the pre-disease state, as regularly reported by the owners: improving vigor (in 53% of cases), activity (78%), mood (91%), appetite (84%), alert state (74%), general welfare (79%), clinical condition (79%) and hematological parameters (78%). This effect lasted as long as the disease was stable or regressing and it was abolished during relapse and disease progression. General welfare was periodically interrupted by 24-48 h by transient flu-like mild symptoms (25%) that often followed local treatment application. Recovery from surgery usually took 48-96 h.
Discussion
In a previous controlled study in more than 100 dogs with canine malignant melanoma, we demonstrated that repeated injections of the suicide gene system and engineered xenogeneic, IL-2-and GM-CSF-secreting cells into the tumor bed, substantially controlled tumor growth and improved disease-free and overall survival in the treated animals compared to untreated, only suicide gene-treated or surgery-treated controls.
14 It has become apparent that despite the potency of the suicide gene therapy system, and the great amplification that can be achieved by cytokine-secreting xenogeneic cells, this treatment by itself has not been enough to fully restrain the disease.
14 Only 16% of patients attained complete sustained remission. The presence of highly heterogeneous residual tumor, allowed extensive heterogeneity, both in the clinical and biological settings. This was supported by the fact that dogs achieving local objective responses had significantly longer overall survival times than non-responders (Table 7) . 14 It is believed that immunotherapy holds the most promise for cancer patients with minimal residual disease. [5] [6] [7] The results of the present study, which appear to be substantially superior to our previous intratumoral treatment, 14 demonstrated that the presence of local disease substantially shortened (Po0.003) patients' median overall survival (Table 7) , supporting this longheld premise.
The current study describes a surgery adjuvant treatment against minimal residual disease by a combination of suicide gene therapy with a subcutaneous vaccine (formolized tumor fragments plus irradiated xenogeneic cells producing hIL-2 and hGM-CSF) for malignant melanoma patients as a promising strategy that offers several advantages.
First, the low response to the herpes simplex thymidine kinase suicide gene (SG), observed in clinical trials may be due to low pro-drug concentration within tumors. [15] [16] [17] We co-delivered lipid-complexed SG with ganciclovir (GCV) increasing the local concentration of the pro-drug that will be readily available for the expressed enzyme.
14 In addition, our small plasmid vector (psCMV, 3.3 kb) contains a minimal proportion of sequences necessary for multiplication in Escherichia coli, its lipofection efficiency being facilitated both in vitro and in vivo.
14 Second, the surgical margin of the cavity after tumor removal was infiltrated with lipid-complexed SG coadministrated with GCV evenly distributed at multiple sites in the surrounding areas and/or in the residual tumor Overall survival due to melanoma: patients that died because of causes unrelated to melanoma progression were censored as alive (no event) until the day of death (Figure 3) . Disease-Free Survival: From Kaplan-Meyer analysis (Figure 4 ), patients were censored as disease-free until the first event (local recurrence or metastases). Both living and dead patients that developed local recurrence or metastases were considered. Patients who have never developed local recurrence or metastases were censored as disease-free on the day of death. Cytoreduction or metastasis present at the initiation of the treatment were considered as event (recurrence or metastasis) at day 1. Recurrence-Free Survival and Metastasis-Free Survival were computed analogously. P-values were calculated by Log-rank test. Figure 4 Kaplan-Meier analysis of disease-free survival. Diseasefree survival (DSC, DCT), recurrence-free survival (RSC, RCT) and metastasis-free survival (MSC, MCT) were censored as described in Table 6 . SC: surgery controls. CT: combined treatment.
Adjuvant combined therapy for canine malignant melanoma LME Finocchiaro and GC Glikin mass. As far as we know, our data demonstrated for the first time in large animals that this new SG-generated margin could significantly delay (Table 5) or prevent (in 49% of CT patients) post-surgical recurrence (Table 3) . This new approach could redefine new (narrow) safety surgical margins. Third, one reason that immunotherapy has met with limited success to control local disease (post-surgery residual or relapsed tumor) may be because of the immunosuppressive tumor microenvironment that inactivated immune cells and triggered their apoptosis. Intra-tumor injections of lipid-complexed SG could circumvent tumor-mediated tolerance and immunosuppression providing an immunostimulatory tumor microenvironment necessary for vaccine-activated immune effector cells to more efficiently destroy residual tumor. 18 Furthermore, cationic lipids and plasmid DNA immunostimulatory sequences might increase tumor immunogenicity. [19] [20] [21] Post-surgery SG therapy sustained by the subcutaneous vaccine, elicited a powerful anti-tumor synergy evidenced by: (i) significant reduction (about 85%, Figure 2 ) in tumor size in those patients presenting objective responses (49%); (ii) significantly increased fraction of patients free of local disease (58% with respect to 6% of surgery-treated controls) and (iii) significant delay in post-surgical recurrence ( Table 5 ). The fact that dogs achieving local response had significantly longer overall survival times than non-responders (Table 7) provides further proof of biological efficacy.
The high rate of regional and distant metastasis is another problem that has hindered long-term control. Systemic therapy may be an appropriate adjunct to local treatment for dogs with malignant melanomas.
Fourth, as a co-adjuvant of SG therapy and to boost the anti-melanoma immune response, we administered a subcutaneous vaccine (SV) composed of autologous and/or allogeneic formalized tumor fragments, with a powerful adjuvant-irradiated xenogeneic cells genetically modified to sustained production of hIL2 and hGM-CSF. [22] [23] [24] [25] [26] In previous experiments, we demonstrated that subcutaneous injection of 3 million hIL-2-secreting CHO cells to healthy Balb/c mice weighing 30 g produced measurable seric hIL-2 for 72 h, with a peak of about 150 pg hIL-2 ml À1 at 48 h. Then, subcutaneously injected xenogeneic cells could easily last 3 days in dog patients. In addition, neither symptoms of acute xenograft rejection nor delayed-type hypersensitivity were observed during treatment.
On the other hand, autologous or allogeneic (from several different patients) whole tumor cell vaccines have the advantage of immunizing the patient with a broader array of tumor surface antigens, increasing the chance of effective immunostimulation. 25 In addition, xenogeneic cells, release of the powerful IL-2 and GM-CSF synergy could promote a strong systemic immune response. [22] [23] [24] [25] [26] Evidence of SV efficacy was the remarkable increase in median overall survival of patients free of local disease (41312 days, n ¼ 49, Table 7 ) whose main difference from the SC group (78 days, n ¼ 51, Table 6 ) was the SV. In addition, SV succeeded in controlling the systemic disease by suppressing distant metastases in 78% of CT patients (Table 4) and delaying their appearance twofold in the remaining 22% (Table 5) .
Fifth, the most stimulating outcome, was the dramatic increase in patients' overall survival and metastasis-free survival times (Figures 3 and 4 ; Table 6 ). Compared to SC patients, the treatment resulted in a significant fivefold increase in median survival. However, survival expectation could be higher in younger patients. When we Overall survival due to melanoma (DM): patients that died because of causes unrelated to melanoma progression were censored as alive (no event) until the day of death (Figure 3 ). Overall survival due to any cause (DAC): all deceased patients were censored as event for Kaplan-Meyer analysis.
P-values were calculated by log-rank test for Kaplan-Meyer analysis. Adjuvant combined therapy for canine malignant melanoma LME Finocchiaro and GC Glikin consider the event as death caused by melanoma, censoring the patients who died from unrelated causes as alive on the day of death (no event), this assumption shifted the survival curve by over 50% beyond 1312 days, precluding the calculation of median survival. This evidence showed a dramatic increase in CT patients' survival expectation by 416.8-fold compared to SC (Table 6 ). Similar result was obtained on metastasis-free survival where the curve also stayed over 50% for more than 1312 days, suggesting that more than 50% of the CT patients would never develop metastasis ( Figure 4 , Table 6 ). It is noteworthy that CT survival times were longer than previously reported for dogs with oral malignant melanoma. Up to date, few statistically significant data on gene therapy for canine melanoma were reported. Surgery and local irradiation followed by intratumoral xenogeneic hIL-2 secreting cells injection (n ¼ 16) resulted in a median survival of 270 days (compared to 75 days of the surgery plus radiation controls). 5 In stage III patients (n ¼ 12), intratumoral injections of cGM-CSF plus superantigen B resulted in a median survival of 168 days (compared to 105 days for surgery controls). 7 After vaccination with allogeneic cells expressing human gp100 (n ¼ 34), dogs experiencing tumor control survived significantly longer than dogs having no response (337 days vs 95 days); 10 while vaccination with xenogeneic human tyrosinase (n ¼ 9) resulted in a median survival of 389 days. 8 Following intratumoral injections of xenogeneic hIL-2 and hGM-CSF secreting cells plus HSV thymidine kinase and ganciclovir (n ¼ 45), dogs presenting local objective responses survived significantly longer than dogs having no response (220 days vs 151 days), both responses being considerably higher than those of SC (82 days).
14 Other approaches displayed encouraging results but the smaller number of patients precludes any statistical analysis. 6, 9 Standard treatments such as radiotherapy or chemotherapy usually gave poor results. A retrospective analysis of dogs with oral melanoma treated with external beam radiation showed that the median time to the first event was 150 days and the median survival was 210 days (n ¼ 140). 27 With an overall response rate of carboplatin (n ¼ 27) of 28%, the median duration of the objective response was 165 days. 28 When combined with platinum-based chemotherapy, hypofractionated radiation therapy yielded a better outcome with a median survival time of 363 days (n ¼ 39). 29 Sixth, the combined treatment did not produce significant damaging collateral effects. Seventh, to be accepted for clinical practice, any new cancer therapy should not only increase the survival lapse but also improve the quality of life. In contrast to other highly toxic therapies our proposed treatment could contribute in both ways. In addition to the prolonged survival, it significantly restored the patient's quality of life, improving general welfare and clinical condition.
This study suggests that the most optimal clinical setting is this surgery adjuvant treatment against minimal residual disease, as an aggressive strategy that not only delays or prevents recurrence and distant metastasis, but substantially extends disease-free and overall survival, with a consequent improvement in life quality. In addition, it supports the utility of spontaneous tumors in companion animals as a valid translational model for the evaluation of novel vaccine therapies.
Further research is necessary to characterize this approach and to determine its suitability for advanced human melanoma.
Materials and methods
Cells
Two engineered Chinese hamster ovary cell lines (CHO-K1, ATCC no. CCL 61) daily producing about 200 ng hIL-2/10 6 cells and 1500 ng hGM-CSF/10 6 cells respectively, were obtained for our laboratory by using a dhfr-driven gene amplification as described. 30, 31 Cells were cultured in T175 flasks at 37 1C in a humidified atmosphere of 95% air and 5% CO 2 with IMDM/F12 medium (Hyclone, Logan, UT, USA) containing 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), 10 mM HEPES (pH 7.4), 2 mM L-glutamine and antibiotics. Serial passages were done by trypsinization (0.25% trypsin and 0.02% EDTA in PBS) of subconfluent monolayers. Before inoculation, cells were exposed to g-rays (5000 rad).
Quality assessment of the cytokine-producing cells comprised determination of in vitro expression levels by ELISA, in vitro biological proliferation assays in the presence of cells secreted molecules, in vivo cytokine plasma expression by s.c. injection in Balb/c mice and mycoplasma control.
ELISA assay
Recombinant hGM-CSF and hIL-2 released to the culture medium was quantified by the ELISA Kit method as described by the manufacturer (R&D Systems, Minneapolis, MN, USA). Cytokine production was expressed as ng/10 6 cells day
À1
, as mean±s.e.m. determined in triplicate.
Plasmids
Plasmids were amplified in E. coli DH5a (Invitrogen, Carlsbad, CA, USA) grown in LB medium containing 100 mg ml À1 neomycin and purified using an ionexchange chromatographic method (Qiagen, Valencia, CA, USA). psCMVtk (4.5 Kb) carries an Eco RI/Bgl II fragment (1.2 Kb) containing HSVtk gene cloned in the sites Eco RI/BamH1 of psCMV (3.3 Kb) downstream of the CMV promoter and upstream of poly A sequences and the kanamycin resistance gene for selection in E. coli. hIL-2 and hGM-CSF genes were subcloned under the CMV promoter of pRc/CMV (Invitrogen) as described. 31 Quality assessment comprised plasmid supercoiling checking by agarose gel electrophoresis, restriction enzymes mapping, in vitro lipofection of cultured cells and in vitro efficacy of the HSVtk/GCV system. 32 Plasmid DNA for injection was resuspended to a final concentration of 2.0 mg ml À1 in sterile PBS.
14 Liposome preparation and in vivo lipofection DMRIE (1,2-dimyristyl oxypropyl-3-dimethyl-hydroxyethilammonium bromide) 33 was synthesized and provided by BioSidus SA (Buenos Aires, Argentina). DOPE (1,2-dioleoyl-sn-glycero-3-phosphatidyl ethanolamine) was purchased from Sigma (St Louis, MO, USA). Liposomes for injection were prepared by combining equimolar amounts of DMRIE and DOPE. The lipids Adjuvant combined therapy for canine malignant melanoma LME Finocchiaro and GC Glikin were evaporated to dryness and liposomes were prepared by reconstitution in sterile Na 2 HPO 4 /NaH 2 PO 4 0.1 M (pH 7.3) to a final concentration of 1.0 mg ml À1 , followed by 10 cycles of 15 s sonication at 4 1C. 34 Before injection, liposomes and plasmid DNA (1:2 v:v) were mixed and allowed to combine at room temperature for 10 min. Then GCV (5 mg mg À1 DNA) was added. It was injected intra-and/or peri-tumorally at multiple sites at a final volume of 1-4 ml, depending on tumor size. 14 
Tumor vaccines preparation
Surgically excised tumors were thoroughly chopped, suspended in 10% neutral formaldehyde for 3 days, exhaustively washed with PBS and homogenized (UltraTurrax IKA, Staufen, Germany). Autologous and/or allogeneic tumor cell preparations were mixed with xenogeneic cytokine producing cells immediately before subcutaneous injection.
Patients
Dogs entered into the study had confirmed histopathological diagnosis of melanoma. The tumors were staged by a veterinary oncologist according to the WHO staging system of stage II (tumors 2-4 cm diameter, negative nodes), stage III (tumor 44 cm and/or positive nodes) or stage IV (distant metastatic disease). All dogs were determined to be free of severe underlying systemic illnesses. During the study, dogs did not receive chemotherapy or another potentially antitumoral or immunosuppressive medication. The dog owners were notified about the experimental nature of the treatment, and all of them granted written informed consent for treatment.
Treatment
A general diagram of the treatment is depicted in Figure  1 . Patients that received combined treatment (n ¼ 100) were subjected to complete or cytoreductive surgery. The surgical margin of the cavity after tumor removal was infiltrated with SG-carrying lipoplexes co-delivered with GCV evenly distributed at multiple sites in the surrounding areas and/or in the residual tumor mass. After 24 and 48 h following SG plus GCV delivery, patients orally took 400-800 mg of acyclovir according to their weight.
Between 5 and 10 days after surgery, patients were clinically controlled and treated once a week for 5 weeks with a subcutaneous vaccine composed of autologous and/or allogeneic formolized tumor cells and irradiated living CHO xenogeneic cells producing 20-30 mg of hIL-2 and hGM-CSF. Patients without local disease continued the treatment only with s.c. vaccine every 14, 28 and 42 days.
Patients with local disease (unresectable or partially removed tumor, unsafe surgery limits or with postsurgical relapse received in the remaining tumor or adjacent areas multiple injections of lipoplexes carrying psCMVtk (1-4 mg DNA) co-delivered with GCV (5-20 mg), according to tumor size. They continued with the chronic treatment or until disappearance of any evidence of local disease. At this point they followed the previous scheme. The follow-up lasted until the patients' death.
Periodic clinical evaluations were performed on every day of treatment and were completed by monthly or bimonthly clinical laboratory analysis. Thoracic radiographs and abdominal echographs were done before treatment and every month according to the patients' response and at longer intervals in long-term surviving animals. Data about treatment efficacy and toxicity were compared to control patients subjected only to surgery (n ¼ 51).
Tumor response criteria
Tumor responses were classified as complete remission, macroscopic disappearance of the tumor; partial remission, reduction of tumor size by more than 50%; stable disease (SD), stabilization or increase in tumor size o50% for at least 125 days after start of treatment; progressive disease, increase of tumor size 450%. Assessment of clinical response has taken into account all measurable lesions. Only complete remission and partial remission were used to determine objective response rate. Complete remission, partial remission and stable disease were included to determine tumor control rate. Tumor volume (evaluated by caliper measuring three diameters) was calculated as 4/3 Â p Â r 1 Â r 2 Â r 3 .
Quality of life
Evaluation was based on the owner's response to a questionnaire completed before every treatment session. The answers for the different aspects were scored: 1 ¼ worse, 2 ¼ no change and 3 ¼ better compared to the pre-disease state. For the sake of simplicity, values of 2 or 3 were considered as a positive effect on the quality of life.
Statistics
Disease-free, metastasis-free and overall median survivals were calculated by Kaplan-Meyer analysis and curves were compared by log-rank test. Response values were compared by Fisher's Exact test. Mean size modifications of tumors after local treatment were analyzed by ANOVA test.
